FDA, EMA To Share Generic Drug Inspection Duties
A joint initiative between the two agencies will allow them to share information on inspections of bioequivalence studies companies submit to gain approval of new generic drugs. The initiative creates a mechanism to conduct joint facility inspections for generic drug applications submitted to both agencies.
Studies submitted for generic drug applications must demonstrate scientifically that a generic drug is...
To view the full article, register now.